Author(s) :

Dawon Kim.

Volume/Issue :

Abstract :

Peanut allergy is potentially a life-threatening condition that places significant clinical and psychological burden on affected children and their families. In spite of the strong efficacy of peanut oral immunotherapy (OIT) shown in increasing tolerance thresholds, the time-dependent progression of desensitization has not been much expressed through a simple quantitative framework. In this study, a first-order dynamic quantitative model has been developed to describe the progression of peanut tolerance during OIT using published aggregate clinical outcomes from the U.S. Food and Drug Administration (FDA) statistical review of Phase 3 Study ARC005. In the referenced trial, 73.5% of AR101-treated participants tolerated at least 600mg of peanut protein at the exit double-blind, placebo-controlled food challenge, where only 6.3% in the placebo group reported it after approximately 12 months of therapy. Assuming that the rate of improvement was proportional to the remaining proportion of participants who had not yet achieved the tolerance endpoint, a first-order differential equation was used to represent the increase in tolerance probability over time. With the fitted model, a desensitization rate constant of approximately 0.111 month-1 and a tolerance half-time of about 6.26 months were produced. The results suggest that a simple first-order mathematical model can provide an interpretable representation of peanut desensitization dynamics during OIT in a population level and also serve as a useful conceptual framework for future modeling studies.